An experimental treatment improves the cognitive ability and gut microbiota of mice with fragile X syndrome
Ongoing treatment with a drug that inhibits the endocannabinoid system peripherally improves memory deficits, reduces synaptic alterations, mitigates gut microbiota dysbiosis and restores intestinal barrier integrity markers in fragile X syndrome mouse models. This experimental approach opens the door to studying a potential therapy to improve the cognitive ability of people who have the syndrome…
Read original article on Medical Xpress - latest medical and health news stories →